XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Insider Trading Arrangements
 3 Months Ended 6 Months Ended
Jun. 30, 2023
shares
Jun. 30, 2023
shares
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement   Dana T. Aftab, our Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer, an officer for purposes of Section 16 of the Exchange Act, entered into a pre-arranged stock trading plan on May 25, 2023. Mr. Aftab’s trading plan provides for the sale of up to 199,256 shares of our common stock (including shares obtained from the exercise of vested stock options covered by the trading plan) between August 24, 2023 and May 23, 2025. This trading plan is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and Exelixis’ policies regarding transactions in Exelixis securities.
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
Dana T. Aftab [Member]    
Trading Arrangements, by Individual    
Name Dana T. Aftab  
Title Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer  
Rule 10b5-1 Arrangement Adopted true  
Adoption Date May 25, 2023  
Arrangement Duration 638 days  
Aggregate Available 199,256 199,256